ArticleMMWR. Morbidity and mortality weekly report2025
Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025.
Article in MMWR. Morbidity and mortality weekly report, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Burden of Respiratory Syncytial Virus in Children With Acute Otitis Media: A Systematic Review and Meta-Analysis.Influenza and other respiratory viruses · 2026Pooled it
- Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025.MMWR. Morbidity and mortality weekly report · 2025Guideline
- Article
- Viral Landscape, Clinical Impact, and Management Trends in Hospitalized Children for Viral-Associated Lower Respiratory Tract Diseases: A Comparative Analysis of Two Post-Pandemic Seasons in Rome, Italy.Journal of medical virology · 2026Observational
- Respiratory Syncytial Virus Immunization Intention During Pregnancy and Infancy.JAMA network open · 2026Article
- Catching our breath: development of interventions and therapies for respiratory syncytial virus.Microbiology and molecular biology reviews : MMBR · 2026Review
- Epidemiology and subtype analysis of respiratory syncytial virus among hospitalized children under five in Isfahan during early 2024.Iranian journal of microbiology · 2026Article
- Factors Affecting Maternal Respiratory Syncytial Virus Vaccination and the Impact on Infant Hospitalization During the 2023-2024 Season in Dallas, Texas.Public health reports (Washington, D.C. : 1974) · 2026Article
- Temporal trends in respiratory syncytial virus-related infant mortality and hospitalizations in the United States.Pediatric research · 2026Article
- Review
- RSV Prevention Products and Severe RSV-Associated Disease Among Infants.JAMA network open · 2026Article
- Review
- Burden, risk factors, and outcomes respiratory syncytial virus (RSV) infection in pediatric intensive care units in Türkiye (RSVP Study 2020-2024).BMC pediatrics · 2026Article
- Respiratory Virus Activity - United States, July 1, 2024-June 30, 2025.MMWR. Morbidity and mortality weekly report · 2026Article
- Manufacturability is access: redesigning antibody production for equitable pediatric access in LMICs.Frontiers in pediatrics · 2026Article
- What should infectious diseases clinicians know about pharmacy benefit managers and their impact on our patients?Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Review
- Reduced Emergency Department Visits and Hospitalizations in Infants after Universal Respiratory Syncytial Virus Immunization, Italy, 2024-25.Emerging infectious diseases · 2026Article
- Reduction in Respiratory Syncytial Virus (RSV)-Related Outpatient and Inpatient Cases Among Infants During the Initial 2024/2025 Season Following Nirsevimab Recommendation in Germany.Influenza and other respiratory viruses · 2026Article
- Epidemiology of respiratory syncytial virus in a German hospital before, during and after the COVID-19 pandemic - a real world monocentric analysis over ten years.Frontiers in pediatrics · 2026Article
- Whole-genome sequence characterization of respiratory syncytial virus in the Johns Hopkins Health System during the 2024-2025 respiratory season.Microbiology spectrum · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors.
Funding
Abstract
Maternal respiratory syncytial virus (RSV) vaccine and nirsevimab, a long-acting monoclonal antibody for infants aged 0-7 months and children aged 8-19 months who are at increased risk for severe RSV disease, became widely available for prevention of severe RSV disease among infants and young children during the 2024-25 RSV season. To evaluate the association between availability of these products and infant and child RSV-associated hospitalization rates, the rates among children aged <5 years were compared for the 2024-25 and 2018-20 RSV seasons using data from the RSV-Associated Hospitalization Surveillance Network (RSV-NET) and New Vaccine Surveillance Network (NVSN). Among infants aged 0-7 months (eligible for protection with maternal vaccination or nirsevimab), 2024-25 RSV-associated hospitalization rates were lower compared with 2018-20 pooled rates (estimated relative rate reductions of 43% [RSV-NET: 95% CI = 40%-46%] and 28% [NVSN: 95% CI = 18%-36%]). The largest estimated rate reduction was observed among infants aged 0-2 months (RSV-NET: 52%, 95% CI = 49%-56%; NVSN: 45%, 95% CI = 32%-57%) and during peak hospitalization periods (December-February). These findings support Advisory Committee on Immunization Practices' recommendations for maternal vaccination or nirsevimab to protect against severe RSV disease in infants and highlight the importance of implementing the recommendations to protect infants as early in the RSV season as possible, before peak transmission, and for infants born during the RSV season, within the first week of life, ideally during the birth hospitalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.